Stockreport

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 [Yahoo! Finance]

Xilio Therapeutics, Inc.  (XLO) 
PDF Consistent with Xilio's clinically-validated masking technology, XTX601 was well tolerated in non-human primates with a favorable therapeutic index WALTHAM, Mass., Ap [Read more]